PARP Inhibitor Biomarkers Market to Grow with a CAGR of 8.74% through 2030
Increase in the prevalence
of breast and ovarian cancer and advancement in diagnostic technology is
expected to drive the Global PARP Inhibitor Biomarkers Market growth in the forecast
period, 2026-2030.
According to
TechSci Research report, “PARP Inhibitor Biomarkers Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2030”,
the Global PARP Inhibitor Biomarkers Market stood at USD 934.10 million in 2024
and is anticipated to grow with a CAGR of 8.74% in the forecast period, 2026-2030.
The market for PARP inhibitor biomarkers is experiencing growth due to the
increasing prevalence of cancer, a rising geriatric demographic, enhanced
awareness about cancer, and strategic initiatives from key competitors and the advancements
in personalized medicine and oncology treatments. These elements are positively
influencing market dynamics.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Global PARP Inhibitor Biomarkers Market”
The rising
incidence of cancer globally, particularly breast and ovarian cancers, has
underscored the need for targeted therapies like PARP inhibitors.
Biomarker-driven approaches, such as testing for BRCA mutations, help identify
patients who are most likely to benefit from PARP inhibitor therapy, thereby
driving market growth. Furthermore, progress in genomic sequencing and
molecular diagnostics has enabled the identification of new biomarkers beyond
BRCA mutations. These biomarkers, such as HRD (Homologous Recombination
Deficiency) status, guide treatment decisions and expand the eligible patient
population for PARP inhibitor therapies, which will further fuel market growth.
The Global PARP
Inhibitor Biomarkers Market is segmented into product, services, application, regional
distribution, and company.
Based on its application,
the breast cancer category holds a leading position in the market of PARP
inhibitor biomarkers primarily driven by the increasing incidence of breast
cancer associated with genetic alterations in BRCA1 or BRCA2 mutations.
According to a WHO report from February 2023, breast cancer is projected to
affect a population of 2.5 million by 2040. It remains one of the most
prevalent cancers among women, accounting for the highest number of
cancer-related deaths in females across 95% of countries. Despite these
statistics, survival rates vary widely, with a significant majority of
fatalities occurring in low- and middle-income nations.
Based on region,
North America holds a dominant position in the PARP inhibitor biomarkers
market, owing to several pivotal factors that underscore its leadership in
advancing personalized medicine and oncology treatments. The region benefits
from a highly advanced healthcare infrastructure, encompassing top-tier hospitals,
research institutions, and diagnostic laboratories equipped with
state-of-the-art technologies. This robust infrastructure facilitates the rapid
adoption and integration of sophisticated biomarker testing technologies
essential for identifying patients eligible for PARP inhibitor therapies based
on genetic mutations such as BRCA1/2.
Moreover, In
Europe, the PARP inhibitor biomarkers market is considered highly promising. As
per the European Cancer Information System (ECIS) in April 2022, about 21% of
breast cancer cases in the region are diagnosed in women under 50 years old,
with the highest incidence observed between ages 50 and 64, accounting for 35%
of cases. The rest of the cases are seen in women aged 65 and older.
Major companies
operating in Global PARP Inhibitor Biomarkers Market are:
- Myriad Genetics, Inc.
- Ambry Genetics
- Thermo Fisher Scientific,
Inc.
- Illumina, Inc.
- CENTOGENE N.V.
- Amoy Diagnostics Co., Ltd.
- Invitae Corporation
- NeoGenomics Laboratories.
- QIAGEN N.V.
- Agilent Technologies, Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
"The evolution of
diagnostic technologies and rising healthcare expenditures are crucial drivers
of the eye health supplements market. In recent years, the growing awareness of
the importance of eye health, particularly related to conditions such as
age-related macular degeneration (AMD) and digital eye strain, has significantly
increased healthcare spending on nutritional interventions and supplements.
Regulatory bodies are updating guidelines and approvals for eye health
formulations, intensifying competition within the market. Moreover, heightened
awareness among consumers and healthcare providers regarding the benefits of
personalized nutrition and targeted eye health solutions has spurred greater
production and marketing efforts in this sector. Manufacturers are increasingly
adopting advanced technologies to enhance nutrient absorption and formulation
efficacy, ensuring efficient production processes. As consumer acceptance
continues to grow and ongoing innovations in supplement formulations and
delivery systems emerge, the eye health supplements market is well-positioned
for robust growth in the coming years”, said Mr. Karan Chechi, Research Director at TechSci
Research, a research-based management consulting firm.
“PARP Inhibitor Biomarkers Market By
Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR
Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others), By Region, By Competition Forecast & Opportunities, 2020-2030F”, has evaluated
the future growth potential of Global PARP Inhibitor Biomarkers Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global PARP Inhibitor Biomarkers Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com